Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV-1

Immunology and Cell Biology

Volumn 84, Issue 2, 2006, Pages 174-183

  Iglesias, Enrique ^a   Thompson, Rafael ^a   Carrazana, Yamilka ^a   Lobaina, Yadira ^a   García, Daymir ^a   Sánchez, Jorge ^a   García, José ^a   Cruz, Otto ^b   Brown, Emma ^a   Martin, Alejandro ^a   Muzio, Verena L ^a   Aguilar, Julio C ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b Laboratory for AIDS Research (LISIDA)   (Cuba)

Author keywords

Adjuvant; AIDS vaccine; Hepatitis B vaccine; Th1 cell

Indexed keywords

ALUMINUM PHOSPHATE; EPITOPE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; VIRUS ANTIGEN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; FEMALE; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; TH1 CELL; VIRUS IMMUNITY;

ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG SYNERGISM; EPITOPES, T-LYMPHOCYTE; FEMALE; HEPATITIS B SURFACE ANTIGENS; HIV-1; IMMUNIZATION; MICE; MICE, INBRED BALB C; MUTANT CHIMERIC PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; VIRAL PROTEINS;

ANIMALIA; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33644782619     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2005.01408.x     Document Type: Article

References (57)

1. Anonymous AIDSVAX fails to prove efficacious in large-scale trial Expert Rev. Anti Infect. Ther 2003 1 527
2. Agwale SM Zeh C Robbins KE et al Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials Vaccine 2002 20 2131 9
3. Bredell H Hunt G Casteling A et al HIV-1 subtype A, D, G, AG and unclassified sequences identified in South Africa AIDS Res. Hum. Retroviruses 2002 18 681 3
4. Cuevas MT Ruibal I Villahermosa ML et al High HIV-1 genetic diversity in Cuba AIDS 2002 16 1643 53
5. Ait-Khaled M Rakik A Griffin P et al Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy Antivir. Ther 2002 7 43 51
6. Aleman S Soderbarg K Visco-Comandini U Sitbon G Sonnerborg A Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy AIDS 2002 16 1039 44
7. Dieterich DT Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection Am. J. Med 1999 107 79S 84S
8. Gilson RJ Hawkins AE Beecham MR et al Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection AIDS 1997 11 597 606
9. Sinicco A Raiteri R Sciandra M et al Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS Scand. J. Infect. Dis 1997 29 111 5
10. Rodriguez-Mendez ML Gonzalez-Quintela A Aguilera A Barrio E Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection Am. J. Gastroenterol 2000 95 1316 22
11. Puoti M Torti C Ripamonti D et al Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome J. Acquir. Immune Defic. Syndr 2003 32 259 67
12. Wit FW Weverling GJ Weel J Jurriaans S Lange JM Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy J. Infect. Dis 2002 186 23 31
13. Milich DR McLachlan A Moriarty A Thornton GB Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg J. Immunol 1987 139 1223 31
14. Halsey NA Reppert EJ Margolis HS Francis DP Fields HA Intradermal hepatitis B vaccination in an abbreviated schedule Vaccine 1986 4 228 32
15. Perrin J Coursaget P Ntareme F Chiron JP Hepatitis B immunization of newborns according to a two dose protocol Vaccine 1986 4 241 4
16. Milich DR Immune response to hepatitis B virus proteins: relevance of the murine model Semin. Liver Dis 1991 11 93 112
17. Schirmbeck R Melber K Kuhrober A Janowicz ZA Reimann J Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo J. Immunol 1994 152 1110 19
18. Ulrich R Nassal M Meisel H Kruger DH Core particles of hepatitis B virus as carrier for foreign epitopes Adv. Virus Res 1998 50 141 82
19. Netter HJ Woo WP Tindle R Macfarlan RI Gowans EJ Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine Vaccine 2003 21 2692 7
20. Birkett A Lyons K Schmidt A et al A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts Infect. Immun 2002 70 6860 70
21. Murray K Shiau AL The core antigen of hepatitis B virus as a carrier for immunogenic peptides Biol. Chem 1999 380 277 83
22. Lau GK Suri D Liang R et al Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen Gastroenterology 2002 122 614 24
23. Hilleman MR Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications Vaccine 2001 19 1837 48
24. Aguilar JC Lobaina Y Muzio V et al Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen Immunol. Cell Biol 2004 82 539 46
25. Lobaina Y Palenzuela D Pichardo D Muzio V Guillen G Aguilar JC Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen Mol. Immunol 2005 42 289 94
26. Riedl P Stober D Oehninger C Melber K Reimann J Schirmbeck R Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain J. Immunol 2002 168 4951 9
27. Letvin NL Walker BD Immunopathogenesis and immunotherapy in AIDS virus infections Nat. Med 2003 9 861 6
28. Belshe RB Stevens C Gorse GJ et al Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher-and lower-risk volunteers J. Infect. Dis 2001 183 1343 52
29. Bruce CB Akrigg A Sharpe SA Hanke T Wilkinson GW Cranage MP Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice J. Gen. Virol 1999 80 2621 8
30. Harrington LE Most Rv R Whitton JL Ahmed R Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope J. Virol 2002 76 3329 37
31. Anonymous Proof of concept IAVI Rep 2004 8 16
32. Day FH Zhang Y Clair P et al Induction of antigen-specific CTL responses using antigens conjugated to short peptide vectors J. Immunol 2003 170 1498 503
33. Kim DT Mitchell DJ Brockstedt DG et al Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide J. Immunol 1997 159 1666 8
34. Iglesias E Ruiz M Carrazana Y et al Chimeric proteins containing HIV-1 T cell epitopes: expression in E. Coli, purification and induction of antibodies in mice J. Biochem. Mol. Biol. Biophys 2001 5 109 20
35. Lobaina Y Garcia D Abreu N Muzio V Aguilar JC Mucosal immunogenicity of the hepatitis B core antigen Biochem. Biophys. Res. Commun 2003 300 745 50
36. Hardy E Martinez E Diago D Diaz R Gonzalez D Herrera L Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris J. Biotechnol 2000 77 157 67
37. Helms T Boehm BO Asaad RJ Trezza RP Lehmann PV Tary-Lehmann M Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients J. Immunol 2000 164 3723 32
38. Storni T Bachmann MF Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison J. Immunol 2004 172 6129 35
39. Wild J Grusby MJ Schirmbeck R Reimann J Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent J. Immunol 1999 163 1880 87
40. Sun Y Iglesias E Samri A et al A systematic comparison of methods to measure HIV-1 specific CD8 T cells J. Immunol. Methods 2003 272 23 34
41. Vazquez-Blomquist D Iglesias E Gonzalez-Horta EE Duarte CA The HIV-1 chimeric protein CR3 expressed by poxviral vectors induces a diverse CD8(+) T cell response in mice and is antigenic for PBMCs from HIV(+) patients Vaccine 2003 22 145 55
42. Riedl P Buschle M Reimann J Schirmbeck R Binding immune-stimulating oligonucleotides to cationic peptides from viral core antigen enhances their potency as adjuvants Eur. J. Immunol 2002 32 1709 16
43. Ogra PL Faden H Welliver RC Vaccination strategies for mucosal immune responses Clin. Microbiol. Rev 2001 14 430 45
44. Jegerlehner A Tissot A Lechner F et al A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses Vaccine 2002 20 3104 12
45. Street M Herd K Londono P et al Differences in the effectiveness of delivery of B- and CTL-epitopes incorporated into the hepatitis B core antigen (HBcAg) c/e1-region Arch. Virol 1999 144 1323 43
46. Spenlehauer C Saragosti S Fleury HJ Kirn A Aubertin AM Moog C Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1 J. Virol 1998 72 9855 64
47. Conley AJ Gorny MK Kessler JA et al Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D J. Virol 1994 68 6994 7000
48. Poignard P Fouts T Naniche D Moore JP Sattentau QJ Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation J. Exp. Med 1996 183 473 84
49. Pinter C Siccardi AG Longhi R Clivio A Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120 AIDS Res. Hum. Retroviruses 1995 11 577 88
50. Stoiber H Schneider R Janatova J Dierich MP Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1 Immunobiology 1995 193 98 113
51. Stoiber H Pinter C Siccardi AG Clivio A Dierich MP Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55) J. Exp. Med 1996 183 307 10
52. Kropelin M Susal C Daniel V Opelz G Inhibition of HIV-1 rgp120 binding to CD4+ T cells by monoclonal antibodies directed against the gp120 C1 or C4 region Immunol. Lett 1998 63 19 25
53. Alsmadi O Tilley SA Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities J. Virol 1998 72 286 93
54. Clerici M Shearer GM The Th1-Th2 hypothesis of HIV infection: new insights Immunol. Today 1994 15 575 81
55. Romagnani S Maggi E Th1 versus Th2 responses in AIDS Curr. Opin. Immunol 1994 6 616 22
56. Lindblad EB Aluminium compounds for use in vaccines Immunol. Cell Biol 2004 82 497 505
57. Ruedl C Schwarz K Jegerlehner A Storni T Manolova V Bachmann MF Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies J. Virol 2005 79 717 24